Waters to Create Laboratory in China for Pharmacopoeia Standards | GenomeWeb

NEW YORK (GenomeWeb) – Waters today announced that it will establish a joint open laboratory with the Chinese Pharmacopoeia Commission.

The lab, which will be located in the Beijing Zhendong Guangming Drug Research Institute, is slated to open by the end of the year. Activities there will be directed at research into pharmacopoeia standards, developing testing methods, validating the methods, and providing training in pharmacopoeia detection methods. The lab, the partners said, is anticipated to become a national technical support center in Chinese pharmaceutical standards.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.